Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Michele Maio, Alfonsus J.M. Van Den EertweghJean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marreaud, Alexander C.J. Van Akkooi, Stefan Suciu, Caroline Robert

Research output: Contribution to journalArticlepeer-review

1379 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science